NCT00492986View on ClinicalTrials.gov

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

PHASE3CompletedINTERVENTIONAL

Enrollment

1,150

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Nexavar (Sorafenib, BAY43-9006)

Multikinase inhibitor: Sorafenib mono therapy 400 mg bid

Trial Locations (33)

1000

Bruxelles - Brussel

1211

Geneva

3000

Leuven

4031

Basel

8000

Århus C

12200

Berlin

20133

Milan

20251

Hamburg

23538

Lübeck

27100

Pavia

28040

Madrid

33000

Bordeaux

33006

Oviedo

40225

Düsseldorf

41124

Modena

42100

Reggio Emilia

55131

Mainz

56068

Koblenz

64276

Darmstadt

66421

Homburg

69008

Lyon

81377

München

94805

Villejuif

01307

Dresden

06156

Perugia

1105 AZ

Amsterdam

04-141

Warsaw

08035

Barcelona

413 45

Gothenburg

171 76

Stockholm

SW3 6JJ

London

G11 6NT

Glasgow

SM2 5PT

Sutton

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY